Wedbush Morgan Downgrades Discovery Laboratories (DSCO) to Sell
More News related to DSCO
- Wedbush Reiterates an 'Underperform' on Discovery Laboratories (DSCO); Financing Overhang Remains;
- Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
- Discovery Labs' Third Quarter 2009 Financial Update
- Discovery Labs Provides Business and Pipeline Development Update
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
Wedbush Morgan downgrades Discovery Laboratories Inc. (Nasdaq: DSCO) from Hold to Sell, after Sufaxin program discontinued and capital restraints remain an issue.
Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases.
Related Categories
DowngradesStocks Mentioned
+0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
